Consequently, this retrospective cohort study aimed to summarize our experience on the use of the two approved anti-IL-23 agents for psoriasis in Greece—risankizumab and guselkumab—over a follow-up period of up to 156 weeks. This evidence concerns the gene IL23A and psoriasis.